Flavivirus Genome Organization, Expression, and Replication

Chambers, Thomas J.; Hahn, Chang S.; Galler, Ricardo; Rice, Charles M.

doi:10.1146/annurev.mi.44.100190.003245

Cited by 1,787 publications

(1,038 citation statements)

References 0 publications

Supporting

Mentioning

984

Contrasting

Unclassified

Order By: Relevance

“…After the fusion event the positive-stranded RNA genome is released into the cytoplasm of the cell. The viral RNA is translated into a single polyprotein [12], which is proteolytically processed to yield three structural proteins (the envelope protein E; the membrane precursor protein prM; and the capsid protein C) and seven non-structural (NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5). Whereas the cleavages at the junctions C-prM, prM-E, E-NS1, NS4A-NS4B [13], and likely also NS1-NS2A [14], are performed by the host signal peptidase located within the lumen of the ER, the remaining peptide bonds are cleaved by the virus encoded NS3 protease.…”

Section: West Nile Virusmentioning

confidence: 99%

Recent progress in West Nile virus diagnosis and vaccination

Filette

Ulbert

Diamond

et al. 2012

Vet Res

138

View full text Add to dashboard Cite

West Nile virus (WNV) is a positive-stranded RNA virus belonging to the Flaviviridae family, a large family with 3 main genera (flavivirus, hepacivirus and pestivirus). Among these viruses, there are several globally relevant human pathogens including the mosquito-borne dengue virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus (JEV) and West Nile virus (WNV), as well as tick-borne viruses such as tick-borne encephalitis virus (TBEV). Since the mid-1990s, outbreaks of WN fever and encephalitis have occurred throughout the world and WNV is now endemic in Africa, Asia, Australia, the Middle East, Europe and the Unites States. This review describes the molecular virology, epidemiology, pathogenesis, and highlights recent progress regarding diagnosis and vaccination against WNV infections.

show abstract

Section: West Nile Virusmentioning

confidence: 99%

Recent progress in West Nile virus diagnosis and vaccination

Filette

Ulbert

Diamond

et al. 2012

Vet Res

138

View full text Add to dashboard Cite

show abstract

“…ZIKV can cause serious health threatening issues to the life of newborns so an efficient vaccine or antiviral drugs need to be designed that can target structural as well as non-structural proteins of ZIKV and help in preventing the infection (Chambers et al, 1990;Leyssen, De Clercq & Neyts, 2000). No FDA approved treatment or vaccine is available for the cure or prevention of this viral infection.…”

Section: Introductionmentioning

confidence: 99%

Prediction of CD8 and CD4 T cell epitopes in the polyprotein of Zika Virus; an immunoinformatics approach

Zaheer¹,

Khan²,

Dar³

et al. 2018

Preprint

View full text Add to dashboard Cite

Background: Zika virus (ZIKV) is an arbovirus that belongs to family Flaviviridae. The virus has emerged as a global threat and no FDA approved vaccine is available, so an efficient vaccine needs to be designed in order to prevent the infection. Computationally designed vaccines can be used for broad-spectrum therapeutics as they can evoke response against viral infections. In the current study, we have predicted antigenic promiscuous T cell epitopes from Zika virus polyprotein using a range of immune-informatics tools and servers.Methods: A total of 238 polyprotein sequences derived from 238 complete genomes were retrieved using NIAID Virus Pathogen Resource and multiple aligned. Using a consensus sequence, the promiscuous CD8-T cell epitopes were predicted from Propred I and CTLPred and their binding affinities were determined by NetMHC4.0. CD4-T cell epitopes were predicted using ProPred and the binding affinities were determined by MHCPred. Antigenicity score and Immunogenicity score was determined from Vaxijen 2.0 and IEDB immunogenicity tool. Homology was found by pBLAST.Results: Among 78 predicted HLA-I binding epitopes, 19 highly antigenic, immunogenic and high-affinity epitopes are prioritized among which 15 are novel vaccine candidates. However, 66 strong HLA-II interacting T cell epitopes are pooled out from 70 predicted epitopes. Among the shortlisted CD4-T cell epitopes 56 epitopes are novel. Conclusion:Epitope-based vaccines are robust and promising candidates against bacterial and viral infections. The predicted epitopes can serve as potential vaccine candidates. Our study shows promising epitopes that can be used to generate stimulate active immune responses in the majority of the human population around the world, However, our results need validation through experimental studies for confirmation. PeerJ Preprints Abstract:Background:

show abstract

“…Hasta el momento se han identificado cuatro serotipos del DENV (DENV 1-4) y todos ellos tienen un genoma de ARN de cadena sencilla y sentido positivo, el cual codifica para una única poliproteína que es procesada para dar lugar a tres proteínas estructurales (C, prM y E) y siete proteínas no estructurales (NS1, NS2A, NS2B, NS3, NS4A, NS4B y NS5) (2,3). El procesamiento de la poliproteína es llevado a cabo por proteasas de la célula huésped y por la proteasa viral, la cual está constituida por el dominio N-terminal de la proteína NS3, que actúa con la proteína NS2B como cofactor (4).…”

unclassified

Polyclonal antibodies against recombinant dengue virus NS3 protein

et al. 2017

View full text Add to dashboard Cite

Introducción. El dengue es una enfermedad causada por uno de los cuatro serotipos del virus del dengue (DENV) y es endémica en, aproximadamente, 130 países. Su incidencia ha aumentado notablemente en las últimas décadas, así como la frecuencia y la magnitud de los brotes. A pesar de los esfuerzos, no existen tratamientos profilácticos ni terapéuticos contra la enfermedad y, en ese contexto, el estudio de los procesos que gobiernan el ciclo de infección del DENV es esencial para desarrollar vacunas o terapias antivirales. Una de las moléculas del DENV más prometedoras es la proteína no estructural 3 (NS3), la cual es indispensable para la replicación viral y es uno de los principales blancos inmunológicos durante la infección. Objetivo. Producir anticuerpos policlonales para contribuir a los futuros estudios sobre las interacciones entre la proteína NS3 y otras proteínas celulares. Materiales y métodos. Se expresaron dos proteínas recombinantes del dominio helicasa de NS3 del DENV de serotipo 2, las cuales se emplearon para inmunizar ratas y producir anticuerpos policlonales. Resultados. Los anticuerpos producidos fueron útiles en ensayos deWestern blot e inmunofluorescencia y se reportó por primera vez un anticuerpo policlonal anti-NS3 que permitió la inmunoprecipitación de la proteína viral y la detecta con Western blot sin necesidad de inducir sobreexpresión de NS3 o de usar extractos de células marcados metabólicamente con radioisótopos. Conclusión. Las proteínas recombinantes expresadas y los anticuerpos producidos constituyen herramientas valiosas para estudiar procesos infecciosos del DENV que involucren a la proteína NS3 y evaluar pruebas dirigidas a interferir las funciones de esta proteína. Polyclonal antibodies against recombinant dengue virus NS3 proteinIntroduction: Dengue is a disease caused by one of four serotypes of the dengue virus (DENV) and is endemic in approximately 130 countries. The incidence of dengue has increased dramatically in recent decades, as well as the frequency and magnitude of outbreaks. Despite all efforts, there are no prophylactic or therapeutic treatments for the disease. Accordingly, research on the processes governing the DENV infection cycle is essential to develop vaccines or antiviral therapies. One of the most attractive DENV molecules to investigate is nonstructural protein 3 (NS3), which is essential for viral replication and a major immune target for infection. Objective: To produce antibodies to support future studies on NS3 and its cellular interactions with other proteins. Materials and methods: Two recombinant proteins of the helicase domain of DENV NS3 serotype 2 were expressed, and used to immunize mice and produce polyclonal antibodies. Results: The antibodies produced were useful in Western blot and immunofluorescence tests. We report an NS3 antibody that immunoprecipitates the viral protein and detects it in Western blot with no need to over-express it or use cell extracts with metabolic radiolabeling.

show abstract

Flavivirus Genome Organization, Expression, and Replication

Cited by 1,787 publications

References 0 publications

Recent progress in West Nile virus diagnosis and vaccination

Recent progress in West Nile virus diagnosis and vaccination

Prediction of CD8 and CD4 T cell epitopes in the polyprotein of Zika Virus; an immunoinformatics approach

Polyclonal antibodies against recombinant dengue virus NS3 protein

Contact Info

Product

Resources

About